Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: Implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project

Chest

Volumn 140, Issue 4, 2011, Pages 911-917

  Gorin, Laurent ^a,c   Fauchier, Laurent ^a,b   Nonin, Emilie ^a,c   Charbonnier, Bernard ^a,b   Babuty, Dominique ^a,b   Lip, Gregory Y H ^d  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 80053508197     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2436     Document Type: Article

References (23)

1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98 (5):476-484.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 (12):857-867. (Pubitemid 351650486)
3. Singer DE, Albers GW, Dalen JE, et al American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133 (suppl 6):546S-592S. (Pubitemid 351892972)
4. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151 (5):297-305.
5. Fuster V, Rydén LE, Cannom DS, et al Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006; 27 (16):1979-2030.
6. Nieuwlaat R, Capucci A, Camm AJ, et al European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26 (22):2422-2434. (Pubitemid 41552972)
7. Fuster V, Rydén LE, Asinger RW, et al American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001; 22 (20):1852-1923.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285 (22):2864-2870. (Pubitemid 32537350)
9. Nieuwlaat R, Olsson SB, Lip GY, et al Euro Heart Survey Investigators; The Euro Heart Survey on Atrial Fibrillation Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J. 2007; 153 (6):1006-1012. (Pubitemid 46823965)
10. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005; 46 (9):1729-1736. (Pubitemid 41531631)
11. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW; The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999; 30 (6):1223-1229. (Pubitemid 29259178)
12. Lip GY, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart. 1996; 75 (2):200-205. (Pubitemid 26068699)
13. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med. 2003; 163(13):1580- 1586.
14. Peterson GM, Boom K, Jackson SL, Vial JH. Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J. 2002; 32 (1-2):15-23. (Pubitemid 36124632)
15. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (suppl 3):429S-456S. (Pubitemid 39302603)
16. De Caterina R, Connolly SJ, Pogue J, et al ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J. 2010; 31 (17):2133-2140.
17. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335 (8):540-546. (Pubitemid 26272308)
18. Lip GY, Huber K, Andreotti F, et al European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting [published correction appears in Thromb Haemost. 2010;104(3):653]. Thromb Haemost. 2010; 103 (1):13-28.
19. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke. 2008; 39(5):1482-1486.
20. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost. 2010; 103 (4):833-840.
21. Camm AJ, Kirchhof P, Lip GY, et al European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31 (19):2369-2429.
22. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008; 1 (3):211-217. (Pubitemid 351804181)
23. Keating RJ, Gersh BJ, Hodge DO, et al. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol. 2005; 96 (10):1420-1424. (Pubitemid 41568627)